Format

Send to:

Choose Destination

Links from PubMed

Follicular thyroid carcinoma(NMTC2)

MedGen UID:
64630
Concept ID:
C0206682
Neoplastic Process
Synonyms: NMTC2; Thyroid cancer, follicular; THYROID CANCER, NONMEDULLARY, 2; THYROID CANCER, NONMEDULLARY, 2, SUSCEPTIBILITY TO; Thyroid carcinoma, follicular, somatic
Modes of inheritance:
Autosomal dominant inheritance
MedGen UID:
141047
Concept ID:
C0443147
Intellectual Product
Sources: HPO, OMIM, Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in heterozygotes. In the context of medical genetics, an autosomal dominant disorder is caused when a single copy of the mutant allele is present. Males and females are affected equally, and can both transmit the disorder with a risk of 50% for each child of inheriting the mutant allele.
Autosomal dominant inheritance (HPO, OMIM, Orphanet)
SNOMED CT: Follicular adenocarcinoma - well differentiated (28173006); Follicular carcinoma - well differentiated (28173006); Follicular thyroid carcinoma (255028004); FTC - Follicular thyroid carcinoma (255028004); Follicular adenocarcinoma, well differentiated (28173006); Follicular carcinoma, well differentiated (28173006); Follicular adenocarcinoma (5257006); Follicular carcinoma (5257006)
 
Genes (locations): HRAS (11p15.5); MINPP1 (10q23.2); NRAS (1p13.2); PTEN (10q23.31); SRGAP1 (12q14.2)
OMIM®: 188470
HPO: HP:0006731

Definition

Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550). [from OMIM]

Clinical features

Follicular thyroid carcinoma
MedGen UID:
64630
Concept ID:
C0206682
Neoplastic Process
Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550).
Non-medullary thyroid carcinoma
MedGen UID:
502247
Concept ID:
C3501843
Neoplastic Process
Abnormality of metabolism/homeostasis
MedGen UID:
867398
Concept ID:
C4021768
Finding
Follicular thyroid carcinoma
MedGen UID:
64630
Concept ID:
C0206682
Neoplastic Process
Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550).
Non-medullary thyroid carcinoma
MedGen UID:
502247
Concept ID:
C3501843
Neoplastic Process

Conditions with this feature

Follicular thyroid carcinoma
MedGen UID:
64630
Concept ID:
C0206682
Neoplastic Process
Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550).

Recent clinical studies

Etiology

Glomski K, Nosé V, Faquin WC, Sadow PM
Endocr Pathol 2017 Jun;28(2):177-185. doi: 10.1007/s12022-017-9483-6. PMID: 28444500
Baek HJ, Kim DW, Lee S, Ryoo I, Lee CY, Choi YJ, Sung JY
Radiol Med 2017 Jul;122(7):530-537. Epub 2017 Mar 14 doi: 10.1007/s11547-017-0753-7. PMID: 28293811
Lang BH, Shek TW, Wu AL, Wan KY
Endocrine 2017 Feb;55(2):496-502. Epub 2016 Dec 7 doi: 10.1007/s12020-016-1188-y. PMID: 27928729
Zwanziger D, Badziong J, Ting S, Moeller LC, Schmid KW, Siebolts U, Wickenhauser C, Dralle H, Fuehrer D
Endocr Relat Cancer 2015 Oct;22(5):819-30. Epub 2015 Jul 28 doi: 10.1530/ERC-14-0502. PMID: 26219679
De Crea C, Raffaelli M, Sessa L, Ronti S, Fadda G, Bellantone C, Lombardi CP
ScientificWorldJournal 2014;2014:952095. Epub 2014 Mar 4 doi: 10.1155/2014/952095. PMID: 24741369Free PMC Article

Diagnosis

Glomski K, Nosé V, Faquin WC, Sadow PM
Endocr Pathol 2017 Jun;28(2):177-185. doi: 10.1007/s12022-017-9483-6. PMID: 28444500
Lang BH, Shek TW, Wu AL, Wan KY
Endocrine 2017 Feb;55(2):496-502. Epub 2016 Dec 7 doi: 10.1007/s12020-016-1188-y. PMID: 27928729
Sathasivam H, Loh YM, Saw CL, Khalid N
Gerodontology 2017 Jun;34(2):276-279. Epub 2016 Jul 7 doi: 10.1111/ger.12240. PMID: 27384017
Makhlouf AM, Chitikova Z, Pusztaszeri M, Berczy M, Delucinge-Vivier C, Triponez F, Meyer P, Philippe J, Dibner C
Oncotarget 2016 Jul 19;7(29):45776-45788. doi: 10.18632/oncotarget.10166. PMID: 27329729Free PMC Article
De Crea C, Raffaelli M, Sessa L, Ronti S, Fadda G, Bellantone C, Lombardi CP
ScientificWorldJournal 2014;2014:952095. Epub 2014 Mar 4 doi: 10.1155/2014/952095. PMID: 24741369Free PMC Article

Therapy

Kim HJ, Mok JO, Kim CH, Kim YJ, Kim SJ, Park HK, Byun DW, Suh K, Yoo MH
Endocr Res 2017 May;42(2):154-162. Epub 2016 Dec 12 doi: 10.1080/07435800.2016.1262395. PMID: 27936964
Zhao Z, Shen GH, Liu B, Kuang AR
Clin Nucl Med 2016 Jan;41(1):e53-5. doi: 10.1097/RLU.0000000000000833. PMID: 26018699
Shen J, Wang S, Zhao X, Shao X, Jiang X, Dai Y, Xu S, Pan X
Int J Clin Exp Pathol 2015;8(11):15285-93. Epub 2015 Nov 1 PMID: 26823882Free PMC Article
Goldstein J, Patel AB, Curry JL, Subbiah V, Piha-Paul S
BMC Dermatol 2015 Feb 13;15:2. doi: 10.1186/s12895-015-0022-1. PMID: 25886034Free PMC Article
Shin SH, Yoon JH, Son MH, Kim SJ, Park SY, Kim HY, Lee HS, Park HJ, Park BK
Thyroid 2012 May;22(5):547-51. Epub 2012 Apr 2 doi: 10.1089/thy.2011.0161. PMID: 22468940

Prognosis

Varadarajan VV, Pace EK, Patel V, Sawhney R, Amdur RJ, Dziegielewski PT
BMC Cancer 2017 Mar 28;17(1):225. doi: 10.1186/s12885-017-3199-3. PMID: 28351395Free PMC Article
Lang BH, Shek TW, Wu AL, Wan KY
Endocrine 2017 Feb;55(2):496-502. Epub 2016 Dec 7 doi: 10.1007/s12020-016-1188-y. PMID: 27928729
Makhlouf AM, Chitikova Z, Pusztaszeri M, Berczy M, Delucinge-Vivier C, Triponez F, Meyer P, Philippe J, Dibner C
Oncotarget 2016 Jul 19;7(29):45776-45788. doi: 10.18632/oncotarget.10166. PMID: 27329729Free PMC Article
Zwanziger D, Badziong J, Ting S, Moeller LC, Schmid KW, Siebolts U, Wickenhauser C, Dralle H, Fuehrer D
Endocr Relat Cancer 2015 Oct;22(5):819-30. Epub 2015 Jul 28 doi: 10.1530/ERC-14-0502. PMID: 26219679
De Crea C, Raffaelli M, Sessa L, Ronti S, Fadda G, Bellantone C, Lombardi CP
ScientificWorldJournal 2014;2014:952095. Epub 2014 Mar 4 doi: 10.1155/2014/952095. PMID: 24741369Free PMC Article

Clinical prediction guides

Makhlouf AM, Chitikova Z, Pusztaszeri M, Berczy M, Delucinge-Vivier C, Triponez F, Meyer P, Philippe J, Dibner C
Oncotarget 2016 Jul 19;7(29):45776-45788. doi: 10.18632/oncotarget.10166. PMID: 27329729Free PMC Article
Zhao L, Zhu XY, Jiang R, Xu M, Wang N, Chen GG, Liu ZM
Int J Clin Exp Pathol 2015;8(9):11236-47. Epub 2015 Sep 1 PMID: 26617848Free PMC Article
De Crea C, Raffaelli M, Sessa L, Ronti S, Fadda G, Bellantone C, Lombardi CP
ScientificWorldJournal 2014;2014:952095. Epub 2014 Mar 4 doi: 10.1155/2014/952095. PMID: 24741369Free PMC Article
Liu J, Brown RE
Int J Clin Exp Pathol 2012;5(3):216-23. Epub 2012 Mar 25 PMID: 22558476Free PMC Article
Pisanu A, Deplano D, Pili M, Uccheddu A
Tumori 2011 May-Jun;97(3):296-303. doi: 10.1700/912.10025. PMID: 21789006

Recent systematic reviews

Varadarajan VV, Pace EK, Patel V, Sawhney R, Amdur RJ, Dziegielewski PT
BMC Cancer 2017 Mar 28;17(1):225. doi: 10.1186/s12885-017-3199-3. PMID: 28351395Free PMC Article
Hu N, Li ZM, Liu JF, Zhang ZZ, Wang LS
Oncotarget 2016 Jul 26;7(30):47750-47759. doi: 10.18632/oncotarget.10282. PMID: 27351286Free PMC Article
Fussey JM, Crunkhorn R, Tedla M, Weickert MO, Mehanna H
Head Neck 2016 Apr;38 Suppl 1:E2297-305. Epub 2015 Sep 3 doi: 10.1002/hed.24218. PMID: 26335228
Nell S, Kist JW, Debray TP, de Keizer B, van Oostenbrugge TJ, Borel Rinkes IH, Valk GD, Vriens MR
Eur J Radiol 2015 Apr;84(4):652-61. Epub 2015 Jan 16 doi: 10.1016/j.ejrad.2015.01.003. PMID: 25638577
Zheng J, Li C, Wang C, Ai Z
Mol Genet Genomics 2015 Jun;290(3):1125-33. Epub 2015 Jan 1 doi: 10.1007/s00438-014-0981-7. PMID: 25552255

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center